Viveo R$1.9 billion IPO
We advised Viveo and the selling shareholders on its IPO and São Paulo Stock Exchange listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
LivaNova $345 million equity offering
We advised the underwriters on the SEC-registered offering
Nurix Therapeutics $150 million at-the-market offering
We advised the sales agent on the stock offering
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Tenaya Therapeutics $207 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Colfax $287.3 million secondary offering
We advised certain selling stockholders on the transaction
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
Royalty Pharma $1.3 billion senior notes offering
We advised Royalty Pharma on its SEC-registered investment-grade notes offering, including $600 million in social bonds
Natera $584.8 million follow-on offering
We advised the underwriters on the SEC-registered stock offering
TScan Therapeutics $100 million IPO
We advised the underwriters on the IPO and Nasdaq listing